Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea

Results of a multicenter retrospective Korean study (KGOG-1005)

H. S. Ryu, S. B. Kang, K. T. Kim, K. H. Chang, J. W. Kim, Jae-Hoon Kim

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The purpose of this study is to review FIGO stage IB2 cervical cancers in Korea for the past 10 years, and evaluate the most frequently employed and appropriate management strategy, and also assess the survival benefits of neoadjuvant chemotherapy (NAC). This is a retrospective chart review of 727 FIGO stage IB2 patients from 1995 to 2005. Six hundred ninety-two patients were enrolled, and all dates on which the patients died were double checked through the "National Registry of Death Statistics" of the Korea National Statistical Office. Management strategies were divided into five groups according to the primary treatment modality. The most frequently employed primary treatment modality for stage IB2 cervical cancer in Korea during the past 10 years was radical hysterectomy (RH). The next was NAC, followed by radiotherapy (RT) and/or extrafascial hysterectomy, concurrent chemoradiotherapy (CCRT) and/or extrafascial hysterectomy, in descending order. The surgery group showed the best results, with an 89% 5-year disease-free survival rate. However, there was no statistical difference between the surgery, NAC, and CCRT groups. For FIGO stage IB2 cervical cancer during the past 10 years in Korea, RH and adjuvant RT or CCRT was the most frequently employed treatment strategy. As a primary modality, RH, NAC, and CCRT showed similar survival rates. However, RH demonstrated the best survival rate among the above treatment strategies.

Original languageEnglish
Pages (from-to)132-136
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume17
Issue number1
DOIs
Publication statusPublished - 2007 Jan 1

Fingerprint

Korea
Hysterectomy
Uterine Cervical Neoplasms
Retrospective Studies
Chemoradiotherapy
Drug Therapy
Survival Rate
Adjuvant Chemoradiotherapy
Adjuvant Radiotherapy
Therapeutics
Disease-Free Survival
Registries
Radiotherapy
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{f265414c82f24417927ed6e454107987,
title = "Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: Results of a multicenter retrospective Korean study (KGOG-1005)",
abstract = "The purpose of this study is to review FIGO stage IB2 cervical cancers in Korea for the past 10 years, and evaluate the most frequently employed and appropriate management strategy, and also assess the survival benefits of neoadjuvant chemotherapy (NAC). This is a retrospective chart review of 727 FIGO stage IB2 patients from 1995 to 2005. Six hundred ninety-two patients were enrolled, and all dates on which the patients died were double checked through the {"}National Registry of Death Statistics{"} of the Korea National Statistical Office. Management strategies were divided into five groups according to the primary treatment modality. The most frequently employed primary treatment modality for stage IB2 cervical cancer in Korea during the past 10 years was radical hysterectomy (RH). The next was NAC, followed by radiotherapy (RT) and/or extrafascial hysterectomy, concurrent chemoradiotherapy (CCRT) and/or extrafascial hysterectomy, in descending order. The surgery group showed the best results, with an 89{\%} 5-year disease-free survival rate. However, there was no statistical difference between the surgery, NAC, and CCRT groups. For FIGO stage IB2 cervical cancer during the past 10 years in Korea, RH and adjuvant RT or CCRT was the most frequently employed treatment strategy. As a primary modality, RH, NAC, and CCRT showed similar survival rates. However, RH demonstrated the best survival rate among the above treatment strategies.",
author = "Ryu, {H. S.} and Kang, {S. B.} and Kim, {K. T.} and Chang, {K. H.} and Kim, {J. W.} and Jae-Hoon Kim",
year = "2007",
month = "1",
day = "1",
doi = "10.1111/j.1525-1438.2007.00803.x",
language = "English",
volume = "17",
pages = "132--136",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea : Results of a multicenter retrospective Korean study (KGOG-1005). / Ryu, H. S.; Kang, S. B.; Kim, K. T.; Chang, K. H.; Kim, J. W.; Kim, Jae-Hoon.

In: International Journal of Gynecological Cancer, Vol. 17, No. 1, 01.01.2007, p. 132-136.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea

T2 - Results of a multicenter retrospective Korean study (KGOG-1005)

AU - Ryu, H. S.

AU - Kang, S. B.

AU - Kim, K. T.

AU - Chang, K. H.

AU - Kim, J. W.

AU - Kim, Jae-Hoon

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The purpose of this study is to review FIGO stage IB2 cervical cancers in Korea for the past 10 years, and evaluate the most frequently employed and appropriate management strategy, and also assess the survival benefits of neoadjuvant chemotherapy (NAC). This is a retrospective chart review of 727 FIGO stage IB2 patients from 1995 to 2005. Six hundred ninety-two patients were enrolled, and all dates on which the patients died were double checked through the "National Registry of Death Statistics" of the Korea National Statistical Office. Management strategies were divided into five groups according to the primary treatment modality. The most frequently employed primary treatment modality for stage IB2 cervical cancer in Korea during the past 10 years was radical hysterectomy (RH). The next was NAC, followed by radiotherapy (RT) and/or extrafascial hysterectomy, concurrent chemoradiotherapy (CCRT) and/or extrafascial hysterectomy, in descending order. The surgery group showed the best results, with an 89% 5-year disease-free survival rate. However, there was no statistical difference between the surgery, NAC, and CCRT groups. For FIGO stage IB2 cervical cancer during the past 10 years in Korea, RH and adjuvant RT or CCRT was the most frequently employed treatment strategy. As a primary modality, RH, NAC, and CCRT showed similar survival rates. However, RH demonstrated the best survival rate among the above treatment strategies.

AB - The purpose of this study is to review FIGO stage IB2 cervical cancers in Korea for the past 10 years, and evaluate the most frequently employed and appropriate management strategy, and also assess the survival benefits of neoadjuvant chemotherapy (NAC). This is a retrospective chart review of 727 FIGO stage IB2 patients from 1995 to 2005. Six hundred ninety-two patients were enrolled, and all dates on which the patients died were double checked through the "National Registry of Death Statistics" of the Korea National Statistical Office. Management strategies were divided into five groups according to the primary treatment modality. The most frequently employed primary treatment modality for stage IB2 cervical cancer in Korea during the past 10 years was radical hysterectomy (RH). The next was NAC, followed by radiotherapy (RT) and/or extrafascial hysterectomy, concurrent chemoradiotherapy (CCRT) and/or extrafascial hysterectomy, in descending order. The surgery group showed the best results, with an 89% 5-year disease-free survival rate. However, there was no statistical difference between the surgery, NAC, and CCRT groups. For FIGO stage IB2 cervical cancer during the past 10 years in Korea, RH and adjuvant RT or CCRT was the most frequently employed treatment strategy. As a primary modality, RH, NAC, and CCRT showed similar survival rates. However, RH demonstrated the best survival rate among the above treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=33846798417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846798417&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.00803.x

DO - 10.1111/j.1525-1438.2007.00803.x

M3 - Article

VL - 17

SP - 132

EP - 136

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 1

ER -